Anticancer research
-
Anticancer research · Nov 1998
ReviewAdvanced head and neck cancer and clinical experience of an effective new agent: docetaxel.
Docetaxel is a taxoid cytotoxic agent known to have considerable clinical activity in a broad range of malignancies. A series of phase I/II studies have been performed to elucidate its toxicity and antitumor activity in advanced squamous cell carcinoma of the head and neck. DOCETAXEL AS FIRST-LINE MONOTHERAPY: Docetaxel administered at 100 mg/m2 as a 1-hour infusion every 3-4 weeks initiated an overall response of 27-42% for a duration of 5-6.5 months in patients with recurrent locoregional or metastatic disease. These results compare favourably with other single-agents in this setting. ⋯ Docetaxel appears to have substantial antitumour activity in advanced head and neck cancer and further studies are justified to determine its full role in the management of this disease.